{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion+%231&page=2",
    "query": {
      "intervention": "Infusion #1",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Infusion+%231&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-19T15:30:38.548Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05376553",
      "title": "Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Locally Advanced Head and Neck Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Krzysztof Misiukiewicz",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2022-07-20",
      "completion_date": "2025-10",
      "has_results": false,
      "last_update_posted_date": "2024-11-18",
      "last_synced_at": "2026-09-19T15:30:38.548Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05376553"
    },
    {
      "nct_id": "NCT01119859",
      "title": "A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Adalimumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo to tocilizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo to adalimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2010-05",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-09-19T15:30:38.548Z",
      "location_count": 33,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 30 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01119859"
    },
    {
      "nct_id": "NCT01669980",
      "title": "Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Infections",
        "Pneumonia"
      ],
      "interventions": [
        {
          "name": "Ceftaroline fosamil",
          "type": "DRUG"
        },
        {
          "name": "IV Ceftriaxone and Vancomycin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Forest Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Months to 18 Years"
      },
      "enrollment_count": 40,
      "start_date": "2012-10",
      "completion_date": "2014-08",
      "has_results": false,
      "last_update_posted_date": "2015-11-02",
      "last_synced_at": "2026-09-19T15:30:38.548Z",
      "location_count": 13,
      "location_summary": "Long Beach, California • Oakland, California • Orange County, California + 10 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Orange County",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01669980"
    },
    {
      "nct_id": "NCT05005403",
      "title": "Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Head and Neck Squamous Cell Carcinoma",
        "Micro Satellite Stable Colorectal Cancer",
        "Gastric/Esophageal Cancer",
        "High-Grade Serous Ovarian Cancer",
        "Pancreatic Cancer",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Azirkitug",
          "type": "DRUG"
        },
        {
          "name": "Budigalimab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Telisotuzumab Adizutecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 694,
      "start_date": "2021-11-01",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-09-19T15:30:38.548Z",
      "location_count": 20,
      "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05005403"
    },
    {
      "nct_id": "NCT01317927",
      "title": "A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Hematological Malignancy"
      ],
      "interventions": [
        {
          "name": "Belinostat, Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2010-12",
      "completion_date": "2015-06",
      "has_results": false,
      "last_update_posted_date": "2015-09-23",
      "last_synced_at": "2026-09-19T15:30:38.548Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01317927"
    },
    {
      "nct_id": "NCT02523131",
      "title": "Home Testing of Day and Night Closed Loop With Pump Suspend Feature",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus",
        "Diabetes Mellitus, Type 1",
        "Glucose Metabolism Disorders",
        "Endocrine System Diseases",
        "Autoimmune Diseases"
      ],
      "interventions": [
        {
          "name": "FlorenceM",
          "type": "DEVICE"
        },
        {
          "name": "Medtronic insulin pump 640G",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "University of Cambridge",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2016-05",
      "completion_date": "2018-03",
      "has_results": false,
      "last_update_posted_date": "2018-03-13",
      "last_synced_at": "2026-09-19T15:30:38.548Z",
      "location_count": 3,
      "location_summary": "Aurora, Colorado • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02523131"
    },
    {
      "nct_id": "NCT00600353",
      "title": "Multi-day Doses in Prevention of Nausea and Emesis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myeloma, Plasma-Cell",
        "Lymphoma, Malignant"
      ],
      "interventions": [
        {
          "name": "Palonosetron",
          "type": "DRUG"
        },
        {
          "name": "Aprepitant",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2007-10",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-09",
      "last_synced_at": "2026-09-19T15:30:38.548Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00600353"
    },
    {
      "nct_id": "NCT01854229",
      "title": "Prometra Post-Approval Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Chronic Pain",
        "Cancer Pain",
        "Intractable Pain",
        "Back Pain"
      ],
      "interventions": [
        {
          "name": "Prometra Programmable Intrathecal Infusion Pump",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Flowonix Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 400,
      "start_date": "2013-06-20",
      "completion_date": "2023-03-15",
      "has_results": false,
      "last_update_posted_date": "2023-10-18",
      "last_synced_at": "2026-09-19T15:30:38.548Z",
      "location_count": 26,
      "location_summary": "La Jolla, California • Santa Barbara, California • Santa Rosa, California + 20 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01854229"
    },
    {
      "nct_id": "NCT00000339",
      "title": "Infusion Laboratory: Protocol 3 (Risperidone) - 4",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute on Drug Abuse (NIDA)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 13,
      "start_date": "1996-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-09-19T15:30:38.548Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00000339"
    },
    {
      "nct_id": "NCT03016377",
      "title": "Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Immune System Diseases",
        "Immunoproliferative Disorders"
      ],
      "interventions": [
        {
          "name": "iC9-CAR19 cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rimiducid",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "3 Years to 70 Years"
      },
      "enrollment_count": 15,
      "start_date": "2012-03-22",
      "completion_date": "2037-09-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-09-19T15:30:38.548Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03016377"
    }
  ]
}